A Phase 4 interventional study of Piflufolastat and PSMA PET/CT Scan in Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer and Prostate Adenocarcinoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by OHSU Knight Cancer Institute · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing piflufolastat in Prostatic Neoplasms — 5 open to participants now, 9 under way, none of them phase 3. piflufolastat · Prostatic Neoplasms.
Among the 24 studies testing piflufolastat in Prostatic Neoplasms, this one is the 11th largest by planned enrollment, is one of 5 that started in 2024, is one of 5 in phase 4, and was the 20th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 24 studies testing piflufolastat in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Akiva Mintz · Sites in United States
Ages 18–120 · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18–100 · Men only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
By country, each count listing its studies:
piflufolastat: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 4 · Phase 4 5
First in 2014; this study’s year is marked. 5 started in 2024.
This study's planned enrollment of 80 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 55 across the 24 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 24 have an industry lead sponsor. The 10 most frequent:
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
43 studies in Prostatic Neoplasms by OHSU Knight Cancer Institute: 4 open now, 7 under way, none of them phase 3. Of 31 finished, 14 (45%) have results posted.
Among the 43 studies in Prostatic Neoplasms by OHSU Knight Cancer Institute, this one is the 8th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 4, and was the 38th registered.
OHSU Knight Cancer Institute’s Prostatic Neoplasms studies by the year they started, since 1998.
1 of the studies testing piflufolastat in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06099093Brigham and Women's HospitalPilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing piflufolastat in Prostatic Neoplasms, from their registry updates:
Among OHSU Knight Cancer Institute’s 43 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.
PRIMARY OBJECTIVE:
I. To determine the early effects (at day 8) of hormonal therapy on PSMA modulation in patients with castration sensitive prostate cancer (CSPC) and castration resistant prostate cancer (CRPC)
SECONDARY OBJECTIVES:
I. To evaluate the effects of hormonal therapy on PSMA modulation at day 28 post-therapy in patients with CSPC and CRPC
II. To evaluate whether the change in PSMA modulation after hormonal therapy initiation changes the tumor staging on PSMA PET as defined by the PROMISE V2 criteria.
EXPLORATORY OBJECTIVES:
I. To assess whether the initial change in PSMA modulation in response to hormonal therapy holds prognostic implications
II. To assess for potential correlation between the early change in PSMA modulation and tumor characteristics such as Gleason score, and site of disease.
III. To assess whether the baseline level of PSMA uptake holds prognostic implications in response to hormonal therapy
OUTLINE:
Patients will be divided (non-randomized) into 2 groups (CRPC or CSPC) and receive PSMA PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.
Participants will be followed for up to 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are planned to receive hormonal therapy within eight weeks of the initial PSMA PET. The hormonal therapy agents include:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with CRPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.
Drug: Piflufolastat · Procedure: PSMA PET/CT Scan · Procedure: PSMA PET/MRI scan · Procedure: Biospecimen Collection · Other: Electronic Health Record Review
Patients with CSPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.
Drug: Piflufolastat · Procedure: PSMA PET/CT Scan · Procedure: PSMA PET/MRI scan · Procedure: Biospecimen Collection · Other: Electronic Health Record Review
Given IV
Also known as: Piflufolastat F-18, Pylarify, 18F-DCFPyL, Fluorine F 18 DCFPyL
Undergo PSMA PET/CT
Also known as: Prostate-Specific Membrane Antigen PET/CT, PSMA PET/CT, PSMA-Positron emission tomography/CT
Undergo PET/MRI
Also known as: Prostate-Specific Membrane Antigen PET/MRI, PSMA PET/MR, PSMA-Positron emission tomography/magnetic resonance imaging
Undergo collection of blood samples
Also known as: Biological Sample Collection, Specimen Collection, Lab draw
Ancillary studies
Change in maximum standardized uptake value (SUVmax) on post-therapy initiation PSMA PET (8 ± 2 days) compared to baseline.
Evaluate the change in SUVmax between baseline and Day 8 using a paired t-test to determine how hormonal therapy affects the PSMA modulation.
Time frame: Baseline PSMA PET up to 8 days after therapy initiation
Change in SUVmax on post-therapy initiation PSMA PET (28 ± 3 days) compared to baseline.
Evaluate the change in SUVmax between baseline and Day 28 using a paired t-test to determine how hormonal therapy affects the PSMA modulation.
Time frame: Baseline PSMA PET up to 28 days after therapy initiation
Number of patients in whom the tumor staging changed on PSMA PET scans obtained post-therapy initiation relative to baseline PET scan
Time frame: Baseline PSMA PET up to 28 days after therapy initiation
Started Jun 2024 (actual). Primary completion is estimated for Sep 2028, 50 months after the start.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Piflufolastat
OHSU Knight Cancer Institute →